CalciMedica, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies. The company’s Form 8-K reports cover results of operations and financial condition, clinical program events involving Auxora, and related updates for inflammatory and immunologic disease programs.
The filing record also includes capital-structure and governance disclosures, including Nasdaq continued-listing compliance matters, at-the-market offering documentation, shareholder voting matters, and the company’s common stock registration on The Nasdaq Capital Market under the symbol CALC.
CalciMedica, Inc. reported that Chief Business Officer and 10% owner Eric W. Roberts received an option grant covering 83,358 shares of common stock. The employee stock option has an exercise price of $0.585 per share and expires on April 4, 2036.
According to the vesting terms, beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over four years. No shares will vest until the company files a Form S-8 covering shares automatically added under its 2023 Equity Incentive Plan pursuant to an annual evergreen provision.
CalciMedica, Inc. reported that President and COO Michael J. Dunn received an employee stock option grant for 65,124 shares of common stock at an exercise price of $0.585 per share. The option expires on April 4, 2036 and vests in monthly installments over four years, beginning April 1, 2026, after a Form S-8 is filed to cover shares added under the company’s 2023 Equity Incentive Plan evergreen provision.
CalciMedica, Inc. reported that Chief Scientific Officer Kenneth A. Stauderman received an employee stock option grant for 65,124 shares of common stock at an exercise price of $0.585 per share. The option expires on April 4, 2036.
Beginning April 1, 2026, 1/48 of the option vests in equal monthly installments over four years. Vesting will not begin until a Form S-8 is filed covering shares automatically added on January 1, 2026 under the company’s 2023 Equity Incentive Plan evergreen provision.
CalciMedica, Inc. director and chief executive officer Rachel A. Leheny received a grant of 148,482 employee stock options to buy common stock at an exercise price of $0.585 per share. The options expire on April 4, 2036.
Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over four years. No shares will vest until a Form S-8 is filed for shares automatically added to the company’s 2023 Equity Incentive Plan on January 1, 2026.
CalciMedica, Inc. reported that Nasdaq has notified the company it no longer meets multiple continued listing standards for the Nasdaq Capital Market. The market value of its listed securities has stayed below the $35,000,000 minimum for 30 consecutive business days, triggering a 180-day cure period ending on September 9, 2026.
The company can regain compliance by meeting any of the alternatives: stockholders’ equity of at least $2,500,000, market value of listed securities of at least $35,000,000, or net income from continuing operations of $500,000 in the relevant periods. Separately, Nasdaq also notified CalciMedica that its common stock has traded below the $1.00 minimum bid price for 30 consecutive business days, starting another 180-day grace period through September 14, 2026 to restore the bid price for at least 10 consecutive business days.
The stock continues to trade on Nasdaq under the symbol CALC, but failure to regain compliance could lead to delisting. The company plans to monitor the requirements and is considering options such as a reverse stock split, while noting there is no assurance it will successfully regain or maintain compliance.
CalciMedica, Inc. has filed a shelf registration prospectus to offer, from time to time, up to $125,000,000 of common stock, preferred stock, debt securities and/or warrants.
The filing states offerings will be made in one or more offerings with specific terms provided in prospectus supplements; sales are described as issuer offerings and proceeds are for the issuer’s general corporate purposes. The company’s common stock trades on Nasdaq under the symbol CALC (last reported sale $0.507 per share on March 2, 2026).
CalciMedica, Inc. is a clinical-stage biopharmaceutical company developing calcium release-activated calcium (CRAC) channel inhibitors, led by its intravenous candidate Auxora for acute pancreatitis and other critical inflammatory conditions. The company has never generated product revenue and discloses a history of net losses with substantial doubt about its ability to continue as a going concern without significant additional capital.
Auxora has shown encouraging Phase 2 data in acute pancreatitis, severe COVID-19 pneumonia, and pediatric asparaginase-induced pancreatic toxicity, and CalciMedica plans to finalize a pivotal program design in acute pancreatitis in the first half of 2026. A Phase 2 trial in acute kidney injury with acute hypoxemic respiratory failure (KOURAGE) was discontinued in January 2026 after a mortality imbalance, though independent reviewers did not find drug-related toxicity, and the company will discuss future development with the FDA.
CalciMedica is also advancing CM5480, an Orai1-selective CRAC inhibitor, toward an anticipated 2027 IND for pulmonary arterial hypertension and is exploring oral CRAC inhibitors in chronic inflammatory and immunologic diseases. It relies on third-party manufacturers, faces intense competition in inflammation and critical care, and highlights extensive scientific and development risks alongside potential opportunities for strategic partnerships.
CalciMedica Inc. reported a full-year 2025 net loss of $29.6 million, or $1.97 per share, compared with a net loss of $13.7 million in 2024. Research and development spending rose to $15.2 million, while general and administrative expenses fell to $7.9 million.
Cash, cash equivalents and short-term investments totaled $13.0 million as of December 31, 2025, which the company expects will fund its current operating plan into the fourth quarter of 2026. Liabilities increased, including a promissory note and a higher warrant liability, leading to a stockholders’ deficit.
Clinically, the company reported no evidence of drug-related toxicity from the unblinded Phase 2 KOURAGE AKI trial, despite a previously disclosed mortality imbalance and trial discontinuation. Auxora is being advanced toward a pivotal acute pancreatitis program, with design expected to be finalized in the first half of 2026, and CM5480 continues preclinical development for pulmonary arterial hypertension with an IND submission anticipated in 2027.
CalciMedica Inc. (CALC) received an amended Schedule 13G from investment entities affiliated with Deerfield and James E. Flynn. The filing reports beneficial ownership of 653,253 shares of common stock, all issuable upon exercise of warrants held by Deerfield Partners, L.P.
The position represents 4.34% of CalciMedica’s common stock. All reporting persons disclose zero sole voting or dispositive power and shared voting and dispositive power over the same 653,253 shares. They also certify the holdings were not acquired to change or influence control of CalciMedica, characterizing the stake as passive.